anti-Keratin K19, Ks19.1 (A53-B/A2) + positive western blot control

anti-Keratin K19 antibody:Ks 19.1 represents an excellent marker to discriminate glandular epithelial carcinoma from those of different origin. No reaction with hepatocellular carcinoma. Polypeptide reacting: Mr 40 000 polypeptide (keratin K19; formerly also designated cytokeratin 19) of human glandular epithelia. The epitope has been localized on aa. 311-335 (QSQLSMKAALEDTLAETEARFGAQL) of the α-helical fragment.Tumors specifically detected: All tested adenocarcinoma; cholangio carcinoma of liver; renal cell carcinoma; transitional cell carcinoma of the bladder; ovary carcinoma; squamous cell carcinoma of cervix, bronchus and lung (intermediate type); mesothelioma; carcinoid tumor of bronchus; breast carcinoma; thymomaReactivity on cultured cell lines: MCF-7Positive western blot control: Whole Cell Lysate from MCF7 human breast adenocarcinoma cell line.MCF7 whole cell lysate was prepared by homogenization in PBS containing Pefablock.Protein concentration was determined using Bradford assay.Set content: Cat. No. 61010, anti-Keratin K19 mouse monoclonal, Ks19.1 (A53-B/A2), lyophilized, purifiedCat. No. 64008, Positive western blot control: anti-Keratin K19 antibody

• Clonality: Monoclonal
• Host: Mouse
• Reactivity: Human
• Antigen: Keratin K19 of Mr 40 000; from cultured human MCF-7 cells
• Clone: Ks19.1 (A53-B/A2)
• Conjugate: unconjugated
• Isotype: IgG2a

• Quantity: 50 µg anti-Keratin K19 + 50 µg western blot control
• Storage: antibody: short term at 2-8°C; long term in aliquots at -20°C; western blot control: lyophilized at 2-8°C, reconstituted at -20°C; avoid freeze/ thaw cycles for both components

• ELISA (ELISA)
• Immunocytochemistry (ICC)
• Immunohistochemistry (IHC)
• Western Blotting (WB)